Endocrine Abstracts

Introduction: Hypoaldosteronism can be induced by a deficit of aldosterone production (AldDef) or a mineralocorticoid resistance (MinRes). Experts have proposed to use hyperkalemia-based aldosterone values for this purpose. However, there is no a range of aldosterone values indicating one of this type of hypoaldosteronism. In 2008, Adam W. R.1 hypothesized that the factored aldosterone (FAldo) could be useful differentiating hypoaldosteronism secondary to MinRes fro...

Introduction: The multidisciplinary approach of the patients with GEP-NETs is very important, having a fundamental role the participation of the endocrinologist.Methods: Description of cases of GEP-NETs followed in the Service of Endocrinology of the SCCH from 1990 to 2016.Results: 95 patients were included, 53.7% were males, age 61.2 years (IR: 50.5–73.5). The diagnosis was incidental in 53.8%. 27.6% presented clinical secret...

Introduction: Neuroendocrine tumors (NETs) constitute a very heterogeneous group of rare neoplasms, although their incidence has increased in recent years. We describe its evolution and survival.Methods: Retrospective study. All patients with histopathological diagnosis of GEP-NETs performed at the HCSC between 2000 and 2016 were selected, data from the medical history were included. Statistical analysis were done with SPSS.Results...

Introduction: Hypoaldosteronism is characterized by the development of hyperkalemia, but can also induce hypovolemic hyponatremia. Trimethroprim can cause hypoaldosteronism through mineralocorticoid resistance. That hypoaldosteronism can induce hyponatremia in absence of Addison’s disease has been questioned. We studied the electrolyte disturbances found following initiation of trimetroprim therapy.Material and methods: Retrospective, analytical. La...

Introduction: Adrenocortical carcinoma (ACC) is a rare and aggressive tumor that accounts for 0.2% of cancer-related deaths. Case series and prospective studies are very limited due to its low prevalence. Current knowledge is based primarily on the opinions of experts in specialized units. The aim of this study is to perform a descriptive analysis of the management and prognosis of patients with ACC in HCSC in the last 20 years.Material and methods: Eigh...

Introduction: Tolvaptan is the only V2-receptor antagonist authorized for use in Europe in patients with SIADH. Its initiation requires hospitalization. Our goal was to analyze the safety and efficacy of tolvaptan started in a Hospital Day-Ward.Material and methods: Retrospective descriptive study of 33 ambulatory patients with mild/moderate SIADH-induced chronic sustained hyponatremia initiating tolvaptan therapy in the Day-Ward of a tertiary center ove...